Jianerkang Medical Co.,Ltd. (SHA:603205)
China · Delayed Price · Currency is CNY 22.53
+0.74 (3.40%)
At close: Jun 12, 2026
Jianerkang Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,020 | 1,023 | 1,042 | 1,032 | 1,090 | 780.16 |
Other Revenue | 1.59 | 1.59 | 4.02 | 1.4 | 2.77 | 1.88 |
| 1,022 | 1,024 | 1,046 | 1,034 | 1,093 | 782.04 | |
Revenue Growth (YoY) | -4.95% | -2.04% | 1.18% | -5.46% | 39.79% | -51.83% |
Cost of Revenue | 779.9 | 781.76 | 812.39 | 802.61 | 834.8 | 600.08 |
Gross Profit | 241.66 | 242.62 | 233.37 | 230.92 | 258.43 | 181.97 |
Selling, General & Admin | 73.18 | 75.07 | 62.87 | 54.31 | 57.13 | 51.42 |
Research & Development | 40.3 | 40.68 | 40.72 | 36.59 | 35.3 | 28.64 |
Other Operating Expenses | 10.48 | 9.04 | 9.62 | 7.89 | 9.09 | 6.43 |
Operating Expenses | 118.92 | 124.37 | 112.73 | 104.73 | 116.07 | 80.98 |
Operating Income | 122.74 | 118.25 | 120.64 | 126.18 | 142.36 | 100.98 |
Interest Expense | -1.56 | -1.16 | -0.01 | -0.65 | -1.66 | -2.07 |
Interest & Investment Income | 13.02 | 14.16 | 7.61 | 4.35 | 2.67 | 0.45 |
Currency Exchange Gain (Loss) | -6.24 | -6.24 | 6.29 | 8.67 | 28.55 | -7.17 |
Other Non Operating Income (Expenses) | -6.6 | -0.36 | -0.2 | -0.25 | -0.23 | -0.45 |
EBT Excluding Unusual Items | 121.36 | 124.64 | 134.34 | 138.31 | 171.69 | 91.74 |
Gain (Loss) on Sale of Investments | 0.65 | - | - | -16.68 | - | - |
Gain (Loss) on Sale of Assets | 0.48 | 0.56 | 0.43 | 0.03 | -3.02 | 0.13 |
Asset Writedown | -0.27 | -0.13 | -0.07 | -0.07 | -0.07 | -0.12 |
Other Unusual Items | 2.59 | 1.23 | 2.78 | 20.68 | 9.24 | 57.88 |
Pretax Income | 124.89 | 126.38 | 137.69 | 142.62 | 177.83 | 149.63 |
Income Tax Expense | 14.78 | 14.94 | 17.48 | 19.08 | 20.49 | 18 |
Net Income | 110.11 | 111.44 | 120.22 | 123.55 | 157.34 | 131.63 |
Net Income to Common | 110.11 | 111.44 | 120.22 | 123.55 | 157.34 | 131.63 |
Net Income Growth | -11.25% | -7.31% | -2.69% | -21.48% | 19.53% | -65.75% |
Shares Outstanding (Basic) | 155 | 157 | 124 | 117 | 117 | 117 |
Shares Outstanding (Diluted) | 155 | 157 | 124 | 117 | 117 | 117 |
Shares Change (YoY) | 14.91% | 26.64% | 5.71% | 0.21% | -0.01% | 12.43% |
EPS (Basic) | 0.71 | 0.71 | 0.97 | 1.05 | 1.34 | 1.13 |
EPS (Diluted) | 0.71 | 0.71 | 0.97 | 1.05 | 1.34 | 1.13 |
EPS Growth | -22.77% | -26.80% | -7.95% | -21.64% | 19.54% | -69.53% |
Free Cash Flow | 74.89 | 88.81 | 101.35 | 73.62 | 96.7 | 21.96 |
Free Cash Flow Per Share | 0.48 | 0.57 | 0.82 | 0.63 | 0.83 | 0.19 |
Dividend Per Share | 0.250 | 0.250 | 0.351 | - | - | - |
Dividend Growth | -28.78% | -28.78% | - | - | - | - |
Gross Margin | 23.66% | 23.69% | 22.32% | 22.34% | 23.64% | 23.27% |
Operating Margin | 12.02% | 11.54% | 11.54% | 12.21% | 13.02% | 12.91% |
Profit Margin | 10.78% | 10.88% | 11.50% | 11.95% | 14.39% | 16.83% |
Free Cash Flow Margin | 7.33% | 8.67% | 9.69% | 7.12% | 8.85% | 2.81% |
EBITDA | 167.66 | 162.72 | 163.31 | 167.13 | 179.2 | 133.4 |
EBITDA Margin | 16.41% | 15.88% | 15.62% | 16.17% | 16.39% | 17.06% |
D&A For EBITDA | 44.93 | 44.48 | 42.67 | 40.95 | 36.84 | 32.41 |
EBIT | 122.74 | 118.25 | 120.64 | 126.18 | 142.36 | 100.98 |
EBIT Margin | 12.02% | 11.54% | 11.54% | 12.21% | 13.02% | 12.91% |
Effective Tax Rate | 11.83% | 11.82% | 12.69% | 13.38% | 11.52% | 12.03% |
Revenue as Reported | 1,022 | 1,024 | 1,046 | 1,034 | 1,093 | 782.04 |
Advertising Expenses | - | 2.15 | 3.14 | 2.16 | 2.84 | 3.15 |